Acquires -Acquired

Sanofi Buys Kadmon Pharmaceuticals for $1.9 Billion

September 10, 2021

Sanofi has dropped $1.9 billion to acquire New York-based Kadmon Pharmaceuticals and its first-in-class oral kinase inhibitor, Rezurock (belumosudil), approved in July to treat chronic graft-vs.-host disease (cGVHD).

Rezurock will be the third drug in Sanofi’s transplant lineup. The once-daily oral medication is the first inhibitor of the Rho-associated coiled-coil kinase 2 (ROCK2) enzyme that influences both inflammation and fibrosis. It’s indicated for adults and children 12 years and older with cGVHD who have failed at least two prior treatments.

A phase 2 study is also investigating the molecule as a treatment for diffuse cutaneous systemic sclerosis.

The acquisition is part of Sanofi’s push to strengthen its general medicines business, said Olivier Charmeil, Sanofi’s executive vice president of general medicines.

View today's stories